IXC
$8M170mo
Invex Therapeutics
Biotechnology · Neurology
Developing Presendin (repurposed drug) for idiopathic intracranial hypertension (IIH). Phase 3 trial terminated early; reassessing strategy.
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$4.5M
Mar 2026 4C
Runway
170moSTABLE
Based on Mar 2026 4C
Market Cap
$8M
Burn Rate
$0.1M/qtr
Mar 2026 4C
Shares Outstanding
75M
Pipeline Assets
1
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveQuarterly 4C24 Apr 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Cash$4.5M·Burn$0.1M/q·OCF$-0.1M
3M Price
IXC.ASX$0.091-13.3% 3M
Low $0.090High $0.130
Pipeline Assets (1)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Catalysts (2)· 1 upcoming · 1 past
Presendin IP/asset divestment or licensing deal
UpcomingSpeculativearrow_upwardHigh31 Dec 2026
expand_more1 past catalyst
Completed
Confirmedarrow_upwardHigh13 Apr 2026
Results available at https://clinicaltrials.gov/study/NCT05347147
| Event | Type |
|---|
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High70/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filed 2 of 2 4Cs on time· statutory deadline
What drove these scores · rolling 2yr
arrow_drop_down
Volatile burn rate — 69% quarterly variation — inconsistent spend
arrow_drop_down
High admin overhead — Only 15% of opex directed to R&D
arrow_drop_up
Burn reductions achieved — 1 quarter with >30% spend reduction
·
Phase 3+ thresholds — Burn rate variability thresholds adjusted for late-stage development
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Announcements(7)
payments
Quarterly 4CPSauto_awesome
Quarterly Activities/Appendix 4C Cash Flow Report24 Apr 2026
expand_more685KB